The policy framework is moving from general scrutiny to enforceable restrictions. Procurement bans tied to the Pentagon's list take effect in June 2026 for direct procurement and June 2027 for indirect procurement. Treasury's updated interpretation of "foreign entities of concern" now extends beyond majority ownership to capture influence through licensing, supply dependence, software, financing, and contractual control—a material expansion of compliance risk. The specific contours of how these rules will apply to individual transactions remain unsettled.
For biotech and pharma firms, the practical consequence is immediate. Any company with China-linked R&D, manufacturing, licensing, financing, or collaboration arrangements now faces heightened investment-screening scrutiny, procurement disqualification, and expanded diligence requirements. The regulatory threshold has shifted from ownership alone to any material form of control or assistance. Counsel should audit existing partnerships, supply chains, and investor bases now, particularly where U.S. government funding or procurement is involved.